Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer

Faye Coe, Vivek Misra, Yamini McCabe, Helen Adderley, Laura Woodhouse, Zaheen Ayub, Xin Wang, Sacha Howell, Maria Ekholm

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Nursing and Health Professions